Smoking Cessation Behavioral Treatment Study
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · May 10, 2019
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of behavioral therapies to help people quit smoking. The first therapy is called Mindfulness-Oriented Recovery Enhancement (MORE), which teaches people how to be more aware of their thoughts and feelings to change their smoking habits. The second therapy is Cognitive Behavioral Therapy (CBT), which helps individuals understand how their thoughts and emotions affect their behavior, including their smoking. The goal of this study is to see which of these methods is more effective in helping smokers quit.
To participate in this study, you need to be at least 18 years old, speak English well enough to understand and follow instructions, and have been a regular smoker for at least two years. You should also be motivated to quit smoking. However, if you have certain medical conditions, are currently taking specific medications, or have a history of serious mental health issues, you may not qualify. If you decide to join, you can expect to engage in therapy sessions that aim to support your journey to quit smoking. This study is currently recruiting participants of all genders, and your involvement could contribute to understanding better ways to help people overcome tobacco addiction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 and up
- • English fluency as demonstrated in providing informed consent and the ability to independently follow directions in completing assigned assessments and tasks
- • Functional vision (with corrective lenses as needed) to complete assigned assessments and tasks
- • Current nicotine dependent smoker with a minimum smoking history of 2 years
- • Interest in quitting smoking
- Exclusion Criteria:
- • Use of psychotropic (e.g. antiepileptic) medications in the past month
- • Positive urine drug screen
- • Presence of an untreated medical illness
- • Current or past psychosis
- • History of major neurological illness or head injury resulting in loss of consciousness
- • And contraindication to MRI, including claustrophobia
- • Among females, positive urine pregnancy test
- • Inability or unwillingness of subject to give informed consent
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charleston, South Carolina, United States
Columbia, Missouri, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials